Equipped with the most complicated state-of-the-art technology from Europe and America, BEACON Pharma will manufacture highest quality anti-cancer drugs at affordable prices.
After meeting the country's demand, the company has a global vision to export its anti-cancer drugs to Europe and the United States.
This was disclosed at the Continuing Medical Education (CME) programme organised by BEACON Pharma, the first and the only high-tech anti-cancer drug manufacturer in Bangladesh.
BEACON Pharma Director (Marketing) Mohammad Akhter Hussain presided over the programme meeting and Product Executive Mamunur Rashid presented the keynote paper on cancer diseases, on the occassion.
BEACON Pharma Product Executive Chowdhury Farhana Faruquee presented another paper on the latest lyophilisation technology.
Among others, BEACON Pharma plant Manager Hisabuddin Ahmed, QA Manager Ahsan Ali Sheikh, Product Promotion Manager AKM Anwarul Hoq and Assistant Sales Manager Zahid Maksud participated in the discussion session.
It was stated that 80 per cent cases of cancer are curable if early diagnosis and treatment can be initiated. At present almost 100 per cent anti-cancer drugs are being imported, which are highly expensive and unaffordable for many patients.
Cancer is a life-threatening disease with a high rate of mortality. Every year around 0.15 million people die of cancer in Bangladesh.
People of both sexes are equally vulnerable to this deadly disease.
Among males prostate cancer is the most prevalent (29 per cent) one followed by lung (16.3 per cent), rectum (11.7 per cent) and bladder cancer (6.6 per cent).
In females, breast cancer accounts for the highest percentage (30.7 per cent) followed by lung, rectum and ovary cancer with 12.5 per cent, 12.2 per cent and 9.8 per cent respectively.